Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
Trials&Research
LATEST NEWS
Parexel and ASAN form Korean alliance
02 February 2012
The CRO Parexel International is upping its game in Asia, by forming an alliance with the Seoul-based ASAN Medical Center (AMC). The collaboration with the South Korean AMC, the parent of seven hospitals which are part of the Asan Foundation established in 1977, will focus primarily on early phase ...
Ergomed partners Hikma for oncology trials in Jordan
26 January 2012
Hikma Pharmaceuticals is to partner with the German full-service CRO Ergomed , which will manage clinical trials of Hikma oncology treatments in a pilot project in Jordan. Ergomed will be conducting the first clinical trials for one of Hikma’s key oncology products in Jordanian hospitals, with ...
Parexel extends early-phase network with UK hospital collaboration
24 January 2012
Parexel International has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom, to expand its early-phase alliance network. The CRO's alliance ...
GSK disputes Argentine fine over baby vaccination scandal
12 January 2012
GlaxoSmithKline is set to appeal a ruling by the Supreme Court of Argentine on the fine it was issued regarding the administrative conduct of the COMPAS (Clinical Otitis Media and PneumoniA Study) study in Mendoza. GSK said it "respectfully disagrees" with the decision, which ruled in favour of ...
>> More Latest News...
FEATURES
Interest persists in new treatments for HCV
01 February 2012
Last year saw the first in a new class of product for treating hepatitis C infections reach the market. Vertex Pharmaceuticals’ Incivek (telaprevir) and Merck & Co’s Victrelis (boceprevir) are protease inhibitors (to be more accurate, they inhibit viral NS3 serine protease, an enzyme required for ...
Improved climate for clinical trials in Thailand
26 January 2012
Incoming Thai Prime Minister Yingluck Shinawatra gained much support from the local pharma community last year on announcing a series of health policy goals. She won the mandate to reform the healthcare and other sectors of the Thai economy after her PTP party’s landslide victory in the July 2011 ...
The red, white, blue and grey of Russian trials
24 November 2011
The Russian law on circulation of medicines, which came into effect in September 2010, brought some clarification to the clinical trial approvals framework, but also a great deal of uncertainty and confusion. One year on, the situation has stabilised in a number of respects, but some grey areas ...
Are you a risk taker?
22 November 2011
Why? With so many maybes in clinical trials, from patient recruitment numbers to site start -up times, there are enough uncertainties that could hamper clinical study success; risk management is one factor that you can bank on. Fiona Racher and Dr John Bennett show how to formulate a system that ...
>> More Features...
PEOPLE
Exco InTouch hires CTO
Exco InTouch , a provider of mobile patient engagement and communication solutions has hired Madhav Vattikuti as Chief Technology Officer (CTO). Vattikuti’s role will see him use his significant technology expertise and background to strengthen delivery and development of Exco InTouch’s market ...
Chiltern adds therapeutic experts to team
The CRO Chiltern International has hired Drs Marcelo Piccirillo and Carlo Lanza to its medical teams. Dr Piccirillo will serve as senior clinical research physician with special emphasis in developing the gastroenterology therapeutic area. He has 20 years experience in the medical and clinical ...
Henauer joins i3 as head of resourcing
PharmaNet/i3 , inVentiv Health’s clinical segment, has hired Dr Stephan Henauer as executive director, i3 Pharma Resourcing. In this role, Dr Henauer will provide leadership for PharmaNet/i3’s staffing business in central, eastern and northern Europe. Prior to joining PharmaNet/i3, Dr Henauer was ...
>> More People...
COMMENTARY
Deals to drive innovation for the next three billion
Deals such as ICON’s recent acquisition of BeijingWits Medical Consulting not only reflect the opportunity presented by emerging growth markets but also the need for local knowledge to conduct business effectively and tailor new product development to local market needs. We expect more deals to ...
Prepare for the regulatory revolution
Every medicine has associated side effects, or adverse drug reactions (ADRs). The European Impact Assessment Report on Pharmacovigilance (PV) estimated that approximately 5% of all hospital admissions are due to ADRs and that ADRs are the fifth most common cause of hospital death, accounting for an ...
CROs: focus on therapeutic areas for project gains
Lifestyle, living standards and longevity will all play their part in the disease profile of the future global population. Aligned with these factors is the shifting market for pharmaceuticals, an increasing proportion of profits will come from outside of the US and Europe as the developing world ...
Navigating the sea of data protection law in European clinical research
In Europe, there is a common set of rules that regulate the collection, use, and sharing of personal data. These include strict protection of sensitive data such as health data. However, individual European countries have interpreted and implemented the rules on the use of health data in clinical ...
Lean strategies for R&D partnership transformation
Lean methods for transformation, believes Deloitte 's Julian Remnant , could form a foundation for multi-company collaborations that might define the next generation of industry partnerships. In my April column, I recognised the benefits R&D organisations have realised from the first generation of ...
Delivery partners will have opportunity to shape sponsor IT strategy
Information technology investments in R&D will begin to target the ‘value analytics’ agenda, believes Deloitte 's Julian Remnant , and to do so, he suggests sponsors will increasingly draw on their delivery partners to shape operational IT strategy. The last ten years has seen industry-wide IT ...
>> More Commentary...
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Partnerships in Clinical Trials
04 March 2012
The Marriott World Center, Orlando, Florida
